A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs LY 3023414 (Primary) ; Necitumumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus First in man; Therapeutic Use
- Sponsors Eli Lilly
- 26 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
- 26 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
- 01 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2017.